Indian Healthcare Industry

Size: px
Start display at page:

Download "Indian Healthcare Industry"

Transcription

1 Indian Healthcare Industry 2012 Synopsis Disclaimer: All information contained in this report has been obtained from sources believed to be accurate by Gyan Research and Analytics Pvt. Ltd. (Gyan). While reasonable care has been taken in its preparation, Gyan makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. The information contained herein may be changed without notice. All information should be considered solely as statements of opinion and Gyan will not be liable for any loss incurred by users from any use of the publication or contents.

2 Synopsis Buoyed by a congenial economic environment and demographic changes, the Indian healthcare industry has experienced exceptional growth over the past few years. In 2010, the industry was valued at USD 50 billion and was projected to grow at a healthy CAGR of 15 percent for the next five years. This momentum is expected to continue and place the sector at the top of the service sector players in India. Globally, the industry is amongst fastest growing sectors, with approximate revenues of USD 5.5 trillion in Within this context, India is viewed as one of the most promising markets among the developing countries and is projected to reach USD 140 billion by This report gives a comprehensive insight into the soaring Indian healthcare industry. It analyses the wide and diverse spectrum of Indian healthcare, with emphasis on opportunities in the areas of hospital infrastructure, pharmaceuticals, medical equipment, diagnostic labs and emerging fields like healthcare tourism, clinical trials & research and telemedicine. The overall industry scenario is upbeat, propelled by a growing economy, shifting demographics, rising disposable incomes, high incidence of lifestyle-induced diseases, new investment avenues and a large pool of talented and cost-effective human resource. The segments that are reaping the most benefits are hospitals, pharmaceuticals, medical equipment companies, pathological labs and other service providers, The Indian government, on its part, is promoting this sector through positive regulations like the introduction of the Health Bill, which proposes to bring all independent bodies like the Medical Council of India (MCI), the Dental Council of India (DCI), the Pharmacy Council of India (PCI) and the Nursing Council of India (NCI) under a centralized authority. The government is also increasing public expenditure on healthcare to 2.5 percent of GDP from 1 percent, encouraging public-private partnerships (PPP) in hospital infrastructure, and boosting medical tourism. Taking advantage of the prevalent optimistic atmosphere, many foreign players are looking to enter the country, especially in Tier-II and Tier-III cities, which have huge untapped markets. Meanwhile, the generic drugs market is set to expand, since most patents are going to expire in the next 5 years. Simultaneously, health cities and single specialty clinics are gaining prominence in 2 P a g e

3 promoting quality healthcare services at affordable prices. Health insurance portability is expected to increase the penetration of insurance by not only improving the quality of service levels, but also by raising competition among insurers to retain customers. Our report also profiles a few of the major players like Apollo Hospitals Group, Fortis Healthcare Group, and Ranbaxy Pharmaceuticals, among others. It looks at the financials of these companies in the context of key growth factors, thereby demonstrating the innate potential of the sector. The report aims to facilitate various international investors interested in the healthcare industry in India. Entrepreneurs who wish to set up hospitals and other components of the entire healthcare value chain and are contemplating entering into healthcare delivery may gain insight into the sector through this report. Interested players who plan to set up pharmaceutical companies, exporters and importers both in India and overseas, banks, industry researchers, analysts, financial institutes offering credit services to the sector, healthcare-related professionals and individual investors tracking different segments of healthcare industry in India may also find this report valuable. SCOPE OF THE REPORT Encompasses the entire healthcare manufacturing and services industry with their market size and share Opportunities in various segments of the industry Outlook of the industry KEY FEATURES DISCUSSED Indian & Global market outlook Growth drivers and trends of the industry Implications of the Union Budget on the industry Emerging fields and their growth trends Comparative Cost Advantage Key Investments and M&A activities in respective segments Export & Import of pharmaceuticals, healthcare products and medical equipment WHY ONE SHOULD BUY Comprehensive outlook of the industry Detailed analysis of all the segments and their opportunities has been discussed Better understanding of the market vis-à-vis market prospects Better positioning of products and service 3 P a g e

4 BENEFICIARIES OF THE REPORT Pharmaceutical Companies and Healthcare Service Providers Educational Institutes Business Research, KPO & Consulting companies Medical Equipment and Devices Manufacturers/Suppliers IT & ITES in Healthcare Sector Medical Practitioners & Clinical Trial Specialists Government and Policy Makers Commercial and Investment Banks Individuals/Investors 4 P a g e

5 Table of Contents 1. Executive Summary 2. Overview 2.1 Global Overview 2.2 Indian Overview 3. Indian Healthcare Industry 3.1 Market Size 3.2 Industry Structure 3.3 Market Segmentation and Trends Market Segmentation Major Trends Healthcare Manufacturing Pharmaceutical Industry Medical Equipment Healthcare-Services The Hospital Service Delivery Health Insurance Sector Diagnostic and Pathological Labs 3.4 Healthcare Infrastructure 3.5 Growth Drivers 3.6 Export-Import Export of Pharmaceutical Products 5 P a g e

6 3.6.2 Export of Medical Equipment Import of Pharmaceutical Products Import of Medical Equipment 4. Critical Success Factors 5. SWOT Analysis 6. Regulatory Norms, Taxes and Duties 6.1 Guidelines for the Pharmaceutical Industry 6.2 Guidelines for the Hospital Industry 6.3 Guidelines for Diagnostic and Pathological Laboratories 6.4 Guidelines for Medical Equipment 6.5 Taxes and Duties 7. Cost Structure 8. Issues and Challenges 9. Opportunities 10. Investments 10.1 Domestic 10.2 Foreign Direct Investment (FDI) 10.3 Private Equity Investments 10.4 Key Mergers and Acquisitions (M&A) 11. Major Players 12. Outlook 6 P a g e

7 List of Charts Chart 1 Historical Global Pharmaceutical Market Size Chart 2 - Forecast of Global Pharmaceutical Industry ( ) Chart 3 Comparison of Global Expenditure on Pharmaceuticals by Segments in 2010 & 2015 Chart 4 - Historical Indian Healthcare Market Size Chart 5 Forecast of Indian Healthcare Industry ( ) Chart 6 Segmentation of Indian Healthcare Market Chart 7 Comparison of Global Expenditure on Healthcare as a Percentage of GDP (2010) Chart 8 - Comparison of Global Healthcare Expenditure (2010) Chart 9 Comparison of Global Per Capita Healthcare Spending on PPP Basis Chart 10 Historical Indian Pharmaceutical Market Size Chart 11 - Forecast of Indian Pharmaceutical Industry ( ) Chart 12 - Segments of Indian Pharmaceutical Industry (2010) Chart 13 Historical Indian Medical Equipment Market Size Chart 14 - Forecast of Indian Medical Equipment ( ) Chart 15 - Historical Indian Hospitals Market Size Chart 16 - Forecast of Indian Hospitals Industry ( ) Chart 17 Historical Allocation of India's Health Budget Chart 18 - Health Insurance Premium (FY2006-FY2011) Chart 19 Segmentation of Health Expenditure in India Chart 20 - Indian Healthcare Delivery Structure Chart 21 - India's GDP Growth Rate Chart 22 - Indian Percentage Share in World GDP Chart 23 - BRIC s Population Growth Rate Chart 24 Prevalence of Lifestyle Diseases in India (2005 & 2015) 7 P a g e

8 Chart 25 Life Expectancy in India (in years) Chart 26 - Export of Pharmaceutical Products (FY2006-FY2011) Chart 27 - Export of Medical Equipment (FY2006-FY2011) Chart 28 - Import of Pharmaceutical Products (FY2006-FY2011) Chart 29 - Import of Medical Equipment (FY2006-FY2011) Chart 30 Forecast of Medical Tourism Market in India ( ) Chart 31 FDI Inflow in Healthcare in India (FY2006-FY2011) Chart 32 M&A Deals in Healthcare ( ) List of Figures Figure 1: Industry Indian Healthcare Industry Structure Figure 2: SWOT Analysis of Indian Healthcare List of Tables Table 1 - Top Five Drug Brands in the World by Sales Table 2 - Major Investments in Biotechnology in India Table 3 Details of Major Medical Equipment Companies in India Table 4 Market Drivers for Health Insurance in India Table 5 - Details of Major Pathological Labs in India Table 6 Comparison of Global Healthcare Infrastructure (2010) Table 7 - Healthcare Infrastructure Indicators in India Table 8 Comparative Cost Structure Table 9 - Comparison of Key Healthcare Procedure Costs Table 10 - Major PE Investments in Healthcare in India ( ) Table 11 Value of M&A Deals in Healthcare in India ( ) Table 12 - Major M&A Deals in Healthcare in India ( ) 8 P a g e

9 Table 13 Financials of Apollo Hospitals Group (FY2006- FY2011) Table 14 - Financials of Fortis Healthcare Group (FY2006- FY2011) Table 15 - Financials of Piramal Healthcare (FY2006- FY2011) Table 16- Financials of Ranbaxy Laboratories Ltd. (FY2006- FY2011) Table 17 - Financials of Dr. Reddy s Laboratories Ltd. (FY2006- FY2011) Table 18 - Financials of Sun Pharmaceuticals (FY2006- FY2011) 9 P a g e

IICCI Short Market Overviews. The Healthcare Industry in India

IICCI Short Market Overviews. The Healthcare Industry in India The Healthcare Industry in India 1. The Healthcare Industry In India healthcare is delivered through both the public sector and private sector. The public healthcare system consists of healthcare facilities

More information

Span Diagnostics Limited

Span Diagnostics Limited Span Diagnostics Limited Date: 5 th January, 216 Stock Performance Details Shareholding Details October 215 Current Price : ` 96.7^ Face Value : ` 1 per share 52 wk High / Low : ` 96.9 / 42.55 Total Traded

More information

GUFIC MANAGEMENT DISCUSSION AND ANALYSIS

GUFIC MANAGEMENT DISCUSSION AND ANALYSIS GUFIC BIOSCIENCES LIMITED MANAGEMENT DISCUSSION AND ANALYSIS Indian Pharma Industry an overview The Indian Pharmaceutical industry has been witnessing phenomenal growth in recent years, driven by rising

More information

Jenburkt Pharmaceuticals Limited

Jenburkt Pharmaceuticals Limited Jenburkt Pharmaceuticals Limited Date: 3 rd February, 2016 Stock Performance Details Shareholding Details October 2015 Current Price : ` 418.0^ Face Value : ` 10 per share 52 wk High / Low : ` 542.8 /

More information

Indian Pharmaceutical Formulations Industry Report,

Indian Pharmaceutical Formulations Industry Report, Indian Pharmaceutical Formulations Industry Report, 2008-2009 India plays an important role in the global pharmaceutical market. In 2005, 2/5 DMFs to FDA were submitted by India. Currently, there are more

More information

Religare Technologies Ltd BSE Scrip Code:

Religare Technologies Ltd BSE Scrip Code: Religare Technologies Ltd BSE Scrip Code: 533525 IT Consulting & Software October 15, 2012 Equity Statistics Current Market Price Rs. 17.05 52 Week High/Low Rs. 44.90/13.70 Market Capitalisation Rs. Crores

More information

Company Overview. Financial Performance

Company Overview. Financial Performance Jan/15 Feb/15 Mar/15 Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 CMP: 43.00 January 11, 2015 Stock Details BSE code 526301 BSE ID MEDINOV Face value ( ) 10 No of shares (m) 9 52 week

More information

HEALTHCARE AND MEDICAL EDUCATION

HEALTHCARE AND MEDICAL EDUCATION HEALTHCARE AND MEDICAL EDUCATION Contents Advantage Jharkhand Healthcare in India Health Indicators Healthcare in Jharkhand PPP-Success stories in Jharkhand Opportunity Landscape in Jharkhand Policy Interventions

More information

Impact on Education and Healthcare Sector Revenue from a 10% Increase in Broadband Penetration in India

Impact on Education and Healthcare Sector Revenue from a 10% Increase in Broadband Penetration in India Presentation for GSMA Impact on Education and Healthcare Sector Revenue from a 10% Increase in Broadband Penetration in India 20 May 2011 Ref: Contents 2 Approach and Results Summary Overview of Education

More information

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%) BUY CMP 1342.40 Target Price 1470.00 APOLLO HOSPITALS ENTERPRISE LTD Result Update (PARENT BASIS): Q3 FY15 MARCH 30 th 2015 ISIN: INE437A01024 Index Details Stock Data Sector Healthcare Facilities BSE

More information

Company Overview. Financial Performance

Company Overview. Financial Performance Jan/15 Feb/15 Mar/15 Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 KMC Speciality Hospitals India Ltd CMP: 7.61 January 21, 2015 Stock Details BSE code 524520 BSE ID KMCSHIL Face value

More information

The Brazil, Russia, India & China Over-the-Counter Pharmaceuticals Market to 2025 **SAMPLE**

The Brazil, Russia, India & China Over-the-Counter Pharmaceuticals Market to 2025 **SAMPLE** The Brazil, Russia, India & China Over-the-Counter Pharmaceuticals Market to 2025 **SAMPLE** Pharmaceutical, commercial and strategic developments in the Brazil, Russia, India & China Over-the- Counter

More information

Bird s Eye View of Indian Pharma

Bird s Eye View of Indian Pharma Bird s Eye View of Indian Pharma Classification of Pharma Industry Pharma industry Formulations Active Pharmaceuticals Ingredients Branded Generics Bulk drugs Pfizer Abbott GSK BMS Teva Mylan Dr Reddy

More information

Tirupati Sarjan Limited

Tirupati Sarjan Limited Tirupati Sarjan Limited Date: 5 th January, 216 Stock Performance Details Shareholding Details September 215 Current Price : ` 27.5^ Face Value : ` 5 per share 52 wk High / Low : ` 29.7 / 1.6 Total Traded

More information

NATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16

NATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16 ISIN: INE987B01018 OCTOBER 15 th, 2015 STOCK DETAILS Sector NATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16 BSE Code 524816 Face Value 10.00 Pharmaceuticals 52wk. High / Low (Rs.) 2709.00/1245.40

More information

Indian Active Pharmaceutical Ingredients (APIs) Industry Report,

Indian Active Pharmaceutical Ingredients (APIs) Industry Report, Indian Active Pharmaceutical Ingredients (APIs) Industry Report, 2008-2009 India plays an important part in the global API market. The API output value of India was US $4.1 billion in 2007, with the CAGR

More information

Dr. Lal PathLabs Limited (DLPL) Q1 FY19 Results Presentation August 10, 2018

Dr. Lal PathLabs Limited (DLPL) Q1 FY19 Results Presentation August 10, 2018 Dr. Lal PathLabs Limited (DLPL) Q1 FY19 Results Presentation August 10, 2018 Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials,

More information

Africa Pharmaceutical

Africa Pharmaceutical Africa Pharmaceutical (title Sector: ) Opportunities and Challenges Dr Feng Zhao Manager, Health Division Human Development Department, African Development Bank 1 The New Africa Economy Africa Rising:

More information

FIDSON HEALTHCARE PLC.

FIDSON HEALTHCARE PLC. FIDSON HEALTHCARE PLC. EQUITY NIGERIA HEALTHCARE GTI Securities Research Coverage Analyst: Morolake Bisi-Afolabi Lead Analyst: Chuks Anyanwu c.anyanwu@gti.com.ng DECEMBER 15 th, 2015 Recommendation: BUY

More information

Dr. Lal PathLabs Limited (DLPL) Q3 & 9M FY18 Results Presentation February 08, 2018

Dr. Lal PathLabs Limited (DLPL) Q3 & 9M FY18 Results Presentation February 08, 2018 Dr. Lal PathLabs Limited (DLPL) Q3 & 9M FY18 Results Presentation February 08, 2018 Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation

More information

India: Great Expectations

India: Great Expectations India: Great Expectations Bangalore, India NEW CHINA: IMPACT OF THE CHINESE CONSUMER India: Great Expectations India is widely expected to be one of the fastest growing economies in the world despite

More information

Healthcare AUGUST For updated information, please visit

Healthcare AUGUST For updated information, please visit 1 Contents Advantage India Market overview and trends Growth drivers Success stories: Apollo Hospitals, Fortis Opportunities Useful information 2 Advantage India Strong demand revenue in India is set to

More information

Alternative Investments Introduction To Real Estate Investments

Alternative Investments Introduction To Real Estate Investments Alternative Investments Introduction To Real Estate Investments Growth( %) India: Growth Engine of the World Economy India is the Seventh largest country in the world in terms of GDP and third largest

More information

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Research Journal of Pharmaceutical, Biological and Chemical Sciences Research Journal of Pharmaceutical, Biological and Chemical Sciences Financial Performance Analysis of Sun Pharma. V Srinivasa Kumar*, R Renganathan, C Vijaya Banu, and V Vijaya Anand. Faculty at School

More information

The Role of the Private Sector in Expanding Health Access to the Base of the Pyramid

The Role of the Private Sector in Expanding Health Access to the Base of the Pyramid The Role of the Private Sector in Expanding Health Access to the Base of the Pyramid ABOUT IFC IFC, a member of the World Bank Group, is the largest global development institution focused exclusively on

More information

Banking NOVEMBER For updated information, please visit

Banking NOVEMBER For updated information, please visit Banking NOVEMBER 1 Contents Advantage India Market overview and trends Growth drivers Success stories: HDFC, Axis Bank Opportunities Useful information 2 Banking NOVEMBER Advantage India Growing demand

More information

BUY AJANTA PHARMA LTD. CMP Target Price JAN. 28 th 2014 SYNOPSIS. Result Update: Q3 FY14

BUY AJANTA PHARMA LTD. CMP Target Price JAN. 28 th 2014 SYNOPSIS. Result Update: Q3 FY14 BUY CMP 940.00 Target Price 1025.00 AJANTA PHARMA LTD. Result Update: Q3 FY14 JAN. 28 th 2014 ISIN: INE031B01031 Index Details Stock Data Sector Pharmaceutical BSE Code 532331 Face Value 5.00 52wk. High

More information

M&A and Capital Raising Outlook S U R V E Y A survey by YES SECURITIES (INDIA) LIMITED, a wholly owned subsidiary of YES BANK LTD.

M&A and Capital Raising Outlook S U R V E Y A survey by YES SECURITIES (INDIA) LIMITED, a wholly owned subsidiary of YES BANK LTD. M&A and Capital Raising Outlook S U R V E Y 2 0 1 7 A survey by YES SECURITIES (INDIA) LIMITED, a wholly owned subsidiary of YES BANK LTD. M&A and Capital Raising OUTLOOK SURVEY 2017 Introduction Over

More information

India: Great Expectations

India: Great Expectations 1 Emerging Market Experts Bangalore, India New China: Impact of The Chinese Consumer India is widely expected to be one of the fastest growing economies in the world despite challenges of poor infrastructure,

More information

Lupin Investor Presentation Q3FY14

Lupin Investor Presentation Q3FY14 Lupin Investor Presentation Q3FY14 Vision: To be an innovation led transnational company Safe harbor statement Materials and information provided during this presentation may contain forward looking statements.

More information

The Poliwogg BioPharma M&A Index

The Poliwogg BioPharma M&A Index The Poliwogg BioPharma M&A Index Q4 2016 Industry Background Scientific Innovations Driving Opportunities: Increasing Understanding of Disease Mechanism Genomics Enabling Precision Medicine Better Therapeutics

More information

Construction Chemicals Market India

Construction Chemicals Market India Construction Chemicals Market India November 2014 Executive Summary Market Construction chemicals market stood at INR xx bn in and is expected to reach INR yy bn in, growing at a CAGR of about z% Growing

More information

UR Associates Research. Indian Radio Cab Market Challenges and Growth Opportunities. Sample Presentation

UR Associates Research. Indian Radio Cab Market Challenges and Growth Opportunities. Sample Presentation UR Associates Research Indian Radio Cab Market 2012 - Challenges and Growth Opportunities Indian radio cab market outlook A Sunrise Industry in India, Indian Radio Cab industry is characterized by huge

More information

Magellan Health: Innovating for Profitable Growth. Jefferies 2015 Healthcare Conference June 2, 2015

Magellan Health: Innovating for Profitable Growth. Jefferies 2015 Healthcare Conference June 2, 2015 Magellan Health: Innovating for Profitable Growth Jefferies 2015 Healthcare Conference June 2, 2015 Cautionary Statement The schedules and statements made in this presentation include forward-looking statements

More information

WHY INDIA? CHAMPION SECTORS PROFILE INVESTMENT OPPORTUNITIES BUSINESS & REGULATORY ENVIRONMENT IN INDIA

WHY INDIA? CHAMPION SECTORS PROFILE INVESTMENT OPPORTUNITIES BUSINESS & REGULATORY ENVIRONMENT IN INDIA SECTOR PROFILE 01 02 03 04 05 WHY INDIA? CHAMPION SECTORS PROFILE INVESTMENT OPPORTUNITIES BUSINESS & REGULATORY ENVIRONMENT IN INDIA 01 WHY INDIA? Focus on infrastructure development Large and growing

More information

Toshihiko Osada General Manager, Strategic Planning Department. Corporate Strategy. Terumo Corporation Dec 12, 2016

Toshihiko Osada General Manager, Strategic Planning Department. Corporate Strategy. Terumo Corporation Dec 12, 2016 2 Toshihiko Osada General Manager, Strategic Planning Department Corporate Strategy Outlook: Medtech Industry Global medtech market: Forecast to grow at a CAGR of 5-6% for the next 10 years, with market

More information

Higher FDI in Indian Insurance sector a buzz for the industry

Higher FDI in Indian Insurance sector a buzz for the industry Higher FDI in Indian Insurance sector a buzz for the industry The view from Transactions and Restructuring By Sam Evans, Global Insurance Transactions and Restructuring Lead, KPMG in Switzerland, Shashwat

More information

India: An Attractive Investment Destination. Department of Industrial Policy and Promotion Ministry of Commerce and Industry

India: An Attractive Investment Destination. Department of Industrial Policy and Promotion Ministry of Commerce and Industry India: An Attractive Investment Destination Department of Industrial Policy and Promotion Ministry of Commerce and Industry Indian economy: growth trajectory Indian economy at USD 4531 Billion (in PPP

More information

INDIAN TERRAIN FASHIONS LTD.(ITFL)

INDIAN TERRAIN FASHIONS LTD.(ITFL) INDIAN TERRAIN FASHIONS LTD.(ITFL) Date :23 rd October, 2012 Stock Performance Details Background Current Price : Rs. 58.0** Face Value : Rs. 10 per share 52 wk High / Low : Rs. 127.00 / Rs. 47.65 Total

More information

Aster DM Healthcare Ltd

Aster DM Healthcare Ltd IPO Note Healthcare Feb 08, 2018 Aster DM Healthcare Ltd Aster DM Healthcare Ltd (ADHL) is one of the largest private healthcare service providers which operates in multiple GCC states and is an emerging

More information

Leadership in life insurance. April 2008

Leadership in life insurance. April 2008 Leadership in life insurance April 2008 Agenda Indian life insurance opportunity Organisational overview Performance highlights 2 Agenda Indian life insurance opportunity Organisational overview Performance

More information

Restile Ceramics Limited

Restile Ceramics Limited Restile Ceramics Limited Date: 5 th January, 216 Stock Performance Details Shareholding Details September 215 Current Price : ` 8.63^ Face Value : ` 1 per share 52 wk High / Low : ` 1.44 / 2.57 Total Traded

More information

Personal Accident and Health Insurance in India, Key Trends and Opportunities to 2018

Personal Accident and Health Insurance in India, Key Trends and Opportunities to 2018 Personal Accident and Health Insurance in India, Key Trends and Opportunities to 2018 Market Intelligence Report Reference code: IS0706MR Published: October 2014 www.timetric.com Timetric John Carpenter

More information

Value over volume The drivers of health care M&A in 2017

Value over volume The drivers of health care M&A in 2017 Value over volume The drivers of health care M&A in 2017 How to win in a thriving deal market Value over volume The drivers of health care M&A in 2017 Gregory Park Partner, US Health Transaction Advisory

More information

Sigma Pharmaceuticals Limited

Sigma Pharmaceuticals Limited Investor Relations Contact: Gary Woodford Corporate Affairs Manager Gary.Woodford@signet.com.au Phone: 03 9215 9632 Mobile: 0417 399 204 Mark Hooper CEO and Managing Director Gary Woodford Corporate Affairs

More information

Small-Cap Research. Atossa Genetics (ATOS-NASDAQ) ATOS: Zacks Company Report OUTLOOK

Small-Cap Research. Atossa Genetics (ATOS-NASDAQ) ATOS: Zacks Company Report OUTLOOK Small-Cap Research March 17, 2017 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Atossa Genetics (ATOS-NASDAQ) ATOS: Zacks Company Report ATOS: A pure

More information

GICS Consultation 2005

GICS Consultation 2005 GICS Consultation 2005 Standard & Poor s and MSCI Consultation Paper on Potential Changes to the Global Industry Classification Standard (GICS ) Structure I. INTRODUCTION MSCI and Standard & Poor s (S&P),

More information

BUY SIMPLEX INFRASTRUCTURES LTD SYNOPSIS. CMP Target Price FEBRUARY 28 th Result Update (PARENT BASIS): Q3 FY15

BUY SIMPLEX INFRASTRUCTURES LTD SYNOPSIS. CMP Target Price FEBRUARY 28 th Result Update (PARENT BASIS): Q3 FY15 BUY CMP 408.40 Target Price 460.00 SIMPLEX INFRASTRUCTURES LIMITED Result Update (PARENT BASIS): Q3 FY15 FEBRUARY 28 th 2015 ISIN: INE059B01024 Index Details Stock Data Sector Construction & Engineering

More information

Florida Health Care Expenditures Report

Florida Health Care Expenditures Report Florida Health Care Expenditures Report 2015 Table of Contents Table of Contents... i Florida Health Care Expenditures in 2015... 1 Introduction... 1 Data and Methodology... 1 Findings... 2 Overall Trend...

More information

Dr. Lal PathLabs Ltd.

Dr. Lal PathLabs Ltd. Dr. Lal Pathlabs Ltd. (DLP) is a provider of diagnostic and related healthcare tests and services in India. It provides a range of diagnostic and related healthcare services which are used in core testing,

More information

WPS HealthyChoices Group Guide. Effective January 1, Be Happy. Live Healthy.

WPS HealthyChoices Group Guide. Effective January 1, Be Happy. Live Healthy. WPS HealthyChoices Group Guide Effective January 1, 2015 Be Happy. Live Healthy. Table of Contents: Introduction 2 Choose 4 Save 5 Control 6 Covered Benefits 7 2 With high-quality coverage, affordable

More information

National Health Expenditure Accounts

National Health Expenditure Accounts National Health Expenditure Accounts Joe Benson, Devin Stone and The NHEA Team American Academy of Actuaries Webinar February 4, 2016 Overview National health spending reached $3.0 trillion, or $9,523

More information

Company Overview. Financial Performance

Company Overview. Financial Performance Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 CMP: 31.25 December 24, 2015 Stock Details BSE code 523878 BSE ID TOTEX Face value ( ) 10 No of shares (m) 8.1 Market

More information

Super Sales India Limited

Super Sales India Limited Super Sales India Limited Date: 20 th January, 2016 Stock Performance Details Shareholding Details September 2015 Current Price : ` 400.0^ Face Value : ` 10 per share 52 wk High / Low : ` 518.0 / 221.6

More information

Cravatex Limited. Stock Performance Details Shareholding Details September 2015

Cravatex Limited. Stock Performance Details Shareholding Details September 2015 Cravatex Limited Date: 20 th January, 2016 Stock Performance Details Shareholding Details September 2015 Current Price : ` 247.8^ Face Value : ` 10 per share 52 wk High / Low : ` 550.0 / 215.0 Total Traded

More information

2008 REPORT. Agreement on the breast cancer test signed with SRL Ranbaxy. Indian multi-centre breast cancer study completed

2008 REPORT. Agreement on the breast cancer test signed with SRL Ranbaxy. Indian multi-centre breast cancer study completed Q2 28 REPORT 1ST HALF-YEAR HIGHLIGHTS: Agreement on the breast cancer test signed with SRL Ranbaxy Indian multi-centre breast cancer study completed NOK 44.8 million share issue European patent granted

More information

BDH Industries Limited BSE Scrip Code:

BDH Industries Limited BSE Scrip Code: BDH Industries Limited BSE Scrip Code: 524828 Pharmaceuticals October 23, 2012 Equity Statistics Current Market Price Rs. 16.95 52 Week High/Low Rs. 21.00/13.15 Market Capitalisation Rs. Crores 9.76 Free

More information

Sanofi India. CMP: INR2,200 TP: INR1,848 Neutral

Sanofi India. CMP: INR2,200 TP: INR1,848 Neutral BSE SENSEX S&P CNX 16,846 5,110 Bloomberg SANL IN Equity Shares (m) 23.0 52-Week Range (INR) 2,430/1,980 1,6,12 Rel. Perf. (%) 3/-3/15 M.Cap. (INR b) 50.7 M.Cap. (USD b) 0.9 26 July 2012 2QCY12 Results

More information

Mergers & Acquisitions

Mergers & Acquisitions Mergers & Acquisitions Shailesh Haribhakti 22 nd February, 2014 Overview of global M&A deals Global M&A activity in 2013 was flat (USD 2.22 trillion vs. USD 2.29 trillion in 2012). However H2 was relatively

More information

Predictive Analytics in the People s Republic of China

Predictive Analytics in the People s Republic of China Predictive Analytics in the People s Republic of China Rong Yi, PhD Senior Consultant Rong.Yi@milliman.com Tel: 781.213.6200 4 th National Predictive Modeling Summit Arlington, VA September 15-16, 2010

More information

Lucintel. Publisher Sample

Lucintel.  Publisher Sample Lucintel http://www.marketresearch.com/lucintel-v2747/ Publisher Sample Phone: 800.298.5699 (US) or +1.240.747.3093 or +1.240.747.3093 (Int'l) Hours: Monday - Thursday: 5:30am - 6:30pm EST Fridays: 5:30am

More information

Future Trends in Employment, Health and Labor

Future Trends in Employment, Health and Labor Future Trends in Employment, Health and Labor PRESENTED BY: Mike Wojcik, MBA,CLU,CFP Senior Vice President Public Sector Practice Group The Horton Group www.thehortongroup.com 1 Agenda Affordable Care

More information

MACRO-ECONOMICS REGULATORY INFRASTRUCTURE PHARMA INDUSTRY

MACRO-ECONOMICS REGULATORY INFRASTRUCTURE PHARMA INDUSTRY MACRO-ECONOMICS Economic growth are potentially good GDP per capita above $ 3.000 Government health budget increases to 5% Middle class category is projected into 150 Mn in 2014, average life expectancy

More information

A Prescription for Investing in Health Care

A Prescription for Investing in Health Care A Prescription for Investing in Health Care HEALTH CARE SECTOR REPORT 23 October 2017 ANALYST(S) Linda D Bannister, CFA John Boylan, CFA Ashtyn Evans, CFA John Nako Buy-rated companies mentioned in this

More information

Scope of Practice & Compensation Report for the Regulatory Profession

Scope of Practice & Compensation Report for the Regulatory Profession 2014 Scope of Practice & Compensation Report for the Regulatory Profession 2014 Scope of Practice & Compensation Report for the Regulatory Profession 1 Contents Introduction... 2 About RAPS... 2 The Survey:

More information

Avenue Supermarts Limited

Avenue Supermarts Limited IPO Note Retail March 4, 2017 Avenue Supermarts Limited A retailer with a growth appetite Avenue Supermarts Ltd (ASL), founded in 2002, is the owner of well established supermarket chain D-Mart. ASL is

More information

HEALTHCARE SERVICES QUARTERLY UPDATE Q4 2018

HEALTHCARE SERVICES QUARTERLY UPDATE Q4 2018 HEALTHCARE SERVICES QUARTERLY UPDATE Q4 2018 Transaction Value ($ Billions) 0.7 0.6 0.4 0.4 2.6 3.2 2.8 4.8 5.9 5.9 6.8 8.2 8.0 10.5 10.3 21.2 Transaction Volume (Number of Deals) INDUSTRY OVERVIEW M&A

More information

LAIDLAW & COMPANY Est. 1842

LAIDLAW & COMPANY Est. 1842 LAIDLAW & COMPANY London New York San Francisco Boston EQUITY RESEARCH Company Report Alimera Sciences (ALIM - $1.07) Impressive Ex-US Sales Help ALIM Exceed Topline Expectations. ALIM recently announced

More information

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%) BUY CMP 1424.75 Target Price 1630.00 MINDTREE LIMITED Result Update (CONSO:IDATED BASIS): Q2 FY16 OCTOBER 17 th 2015 ISIN: INE018I01017 Index Details Stock Data Sector IT Consulting & Software BSE Code

More information

Emerging markets update Coloplast Capital Markets Day 2018 Kristian Villumsen, Executive Vice President, Chronic Care

Emerging markets update Coloplast Capital Markets Day 2018 Kristian Villumsen, Executive Vice President, Chronic Care Emerging markets update Coloplast Capital Markets Day 2018 Kristian Villumsen, Executive Vice President, Chronic Care Introducing Region Emerging Markets Region Emerging Markets at a glance Emerging Markets

More information

General Corporate Criteria

General Corporate Criteria 16 General Corporate Criteria Rating Criteria Scope of the Criteria Lianhe Ratings Global Limited ( Lianhe Global ) applies the general corporate criteria to corporate entities that are not in the industry

More information

Doing Business With India

Doing Business With India Doing Business With India Mahendra Pratap Entry India LLC mpratap@entryindia.com Australia June 3, 2011 Entry India LLC 1 USA Russia China Target Audience SMEs, Start-ups and Individuals Who want to Expand

More information

Two fold growth in PE investments

Two fold growth in PE investments INR, Billion INVESTMENT MARKETBEAT Two fold growth in PE investments INDIA Contents Foreign Direct Investment 1 Private Equity Investments in real estate 2 Investment Volume 2 Investment Type 2 City and

More information

LINCARE HOLDINGS INC.

LINCARE HOLDINGS INC. LINCARE HOLDINGS INC. Forward-Looking Statements Certain statements contained in this presentation constitute forward-looking statements. Such forwardlooking statements are based on management s current

More information

Glance Finance Ltd. Other Financial Services. . Company Overview. Company Fundamentals. Key Strengths. CMP Rs BSE Code BSE ID

Glance Finance Ltd. Other Financial Services. . Company Overview. Company Fundamentals. Key Strengths. CMP Rs BSE Code BSE ID Other Financial Services Nov 15, 2012 CMP Rs. 19.55 BSE Code 531199 BSE ID GLANCE High/Low 1Y (Rs.) 35.15/ 16.55 Average Volume (3M) 279 Market Cap (Rs. Cr.) 6 Shareholding % Sep-12 Jun-12 Promoters 74.83

More information

The Chinese Medtech Market

The Chinese Medtech Market The Chinese Medtech Market 2017-2020 The Reimbursement System as one of the Key Drivers Authors: Helgert Van Raamt VP Partnerships and New Business Bart Van den Mooter CEO TforG Group PAGE 1 @ 2017 TFORG

More information

DIL Ltd. Pharmaceuticals. Company Overview. Company Fundamentals. CMP Rs

DIL Ltd. Pharmaceuticals. Company Overview. Company Fundamentals. CMP Rs Pharmaceuticals September 26, 2012 CMP Rs. 700.4 BSE Code 506414 BSE ID DIL High/Low 1Y (Rs.) 748.2 / 373.9 Average Volume (3M) 579.8 Market Cap (Rs. Cr.) 161.1 Shareholding % Jun-12 Mar-12 Promoters 63.20

More information

Consulate General of India Durban. Trade and Investment Opportunities in India. Focus Area : Medical Tourism

Consulate General of India Durban. Trade and Investment Opportunities in India. Focus Area : Medical Tourism Consulate General of India Durban Trade and Investment Opportunities in India Focus Area : Medical Tourism Economy $2.45 trillion economy. Economic Growth: 7.9% (2015-16); 7.1% in (2016-17) Sectoral contribution

More information

ALEMBIC PHARMACEUTICALS LTD.(APL)

ALEMBIC PHARMACEUTICALS LTD.(APL) ALEMBIC PHARMACEUTICALS LTD.(APL) Date : 13 th September, 212 Stock Performance Details Current Price : Rs. 73.35** Face Value : Rs. 2 per share 52 wk High / Low : Rs. 78.95 / Rs.34. Total Traded Volumes

More information

Healthcare in China The Opportunity for Investment. Chindex International and United Family Healthcare February 2010

Healthcare in China The Opportunity for Investment. Chindex International and United Family Healthcare February 2010 Healthcare in China The Opportunity for Investment Chindex International and United Family Healthcare February 2010 Forward Looking Statements This presentation contains information which may be considered

More information

A Study on GST Impact On Service Sectors With Special Reference To health Care In Mysore City

A Study on GST Impact On Service Sectors With Special Reference To health Care In Mysore City IOSR Journal of Business and Management (IOSR-JBM) e-issn: 2278-487X, p-issn: 2319-7668 PP 56-60 www.iosrjournals.org A Study on GST Impact On Service Sectors With Special Reference To health Care In Mysore

More information

National Health Expenditure Projections

National Health Expenditure Projections National Health Expenditure Projections 2011-2021 Forecast Summary In 2011, national health spending is estimated to have reached $2.7 trillion, growing at the same rate of 3.9 percent observed in 2010,

More information

Overview of Reimbursement Strategies for Novel Medical Technologies

Overview of Reimbursement Strategies for Novel Medical Technologies Overview of Reimbursement Strategies for Novel Medical Technologies Nov 9, 2016 Goals and Objectives Develop understanding of U.S. medical technology reimbursement landscape and provide information about

More information

Shifa International Hospitals Limited (Shifa)

Shifa International Hospitals Limited (Shifa) Rating Report RATING REPORT Shifa International Hospitals Limited (Shifa) REPORT DATE: March 5, 2018 RATING ANALYSTS: Talha Iqbal talha.iqbal@jcrvis.com.pk Muhammad Ibad Desmukh ibad.deshmukh@jcrvis.com.pk

More information

Presenting Never Ending Consumption Story. Participate in One of the biggest consumption market of the World

Presenting Never Ending Consumption Story. Participate in One of the biggest consumption market of the World Presenting Never Ending Consumption Story Participate in One of the biggest consumption market of the World 2 FY51 FY60 FY 70 FY 80 FY 90 FY 00 FY 05 FY 06 FY 07 FY 08 FY 09 FY 10 FY 11 FY 12 FY 13 FY

More information

INDIAN CAPITAL MARKET- BY ANMI (India)

INDIAN CAPITAL MARKET- BY ANMI (India) INDIAN CAPITAL MARKET- BY ANMI (India) 1) ANMI is a pan India association comprising of the trading members across India like National Stock Exchange (NSE), Bombay Stock Exchange (BSE) and other exchanges

More information

Reliance Capital Builder Fund II Series C (A Close Ended Equity Oriented Scheme)

Reliance Capital Builder Fund II Series C (A Close Ended Equity Oriented Scheme) Reliance Capital Builder Fund II Series C (A Close Ended Equity Oriented Scheme) Offer for Sale of Units at Rs.10/- per unit during the new fund offer period Tenure 3 years from the date of allotment of

More information

COMPETITIVE POSITIONING OF THE TOP 10 PLAYERS GROWING ALLIANCES IN BIOPHARMACEUTICALS TABLE 7 KEY LICENSING AND PARTNERSHIP DEALS IN

COMPETITIVE POSITIONING OF THE TOP 10 PLAYERS GROWING ALLIANCES IN BIOPHARMACEUTICALS TABLE 7 KEY LICENSING AND PARTNERSHIP DEALS IN CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 2 INTENDED AUDIENCE... 3 METHODOLOGY AND INFORMATION SOURCES... 3 ANALYST CREDENTIALS...

More information

Company Fundamentals

Company Fundamentals IT Software Products November 16, 2012 *CMP Rs.0.24 BSE Code 532403 BSE ID 4THGEN High/Low 1Y (Rs.) 0.62/0.22 Average Volume (3M) 6457 Market Cap (Rs. Cr.) 1 Shareholding % Sep-12 Jun-12 Promoters 15.32

More information

Campus Forum November 15, 2016 Agenda

Campus Forum November 15, 2016 Agenda Campus Forum November 15, 2016 Agenda Introductions MTIA Dedicated Team Current Plan Design Benchmarking Data Challenges and Considerations Specific Concerns Questions 2 M&T Insurance Agency, Inc. Dedicated

More information

Sanofi India NEUTRAL. Performance Highlights. CMP `4,007 Target Price - 3QCY2017 Result Update Pharmaceutical. Investment Period 12 months

Sanofi India NEUTRAL. Performance Highlights. CMP `4,007 Target Price - 3QCY2017 Result Update Pharmaceutical. Investment Period 12 months 3QCY2017 Result Update Pharmaceutical November 20, 2017 Sanofi India Performance Highlights Y/E Dec. (` cr) 3QCY2017 2QCY2017 % chg (qoq) 3QCY2016 % chg (yoy) Net sales Other income Operating profit 627

More information

ERM , Getzen Economics and Financing (Sec. 5.4, 5.5)

ERM , Getzen Economics and Financing (Sec. 5.4, 5.5) ERM 512-13, Getzen (Sec. 5.4, 5.5) 1/17 Key Points Types of Managed Care Plans Ways to Reduce Costs Features of Managed Care Utilization Review 2/17 Managed Care Plans Why Managed Care? Primary reason

More information

ICICI Group: Performance & Strategy. November 2015

ICICI Group: Performance & Strategy. November 2015 ICICI Group: Performance & Strategy November 2015 Certain statements in these slides are forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty

More information

Sanofi India NEUTRAL. Performance Highlights. CMP `4,007 Target Price - 2QCY2017 Result Update Pharmaceutical. 3-year price chart.

Sanofi India NEUTRAL. Performance Highlights. CMP `4,007 Target Price - 2QCY2017 Result Update Pharmaceutical. 3-year price chart. 2QCY2017 Result Update Pharmaceutical August 28, 2017 Sanofi India Performance Highlights Y/E Dec. (` cr) 2QCY2017 1QCY2017 % chg (qoq) 2QCY2016 % chg (yoy) Net sales Other income Operating profit 556

More information

Religare Invesco Caterpillar Portfolio. September 2015

Religare Invesco Caterpillar Portfolio. September 2015 Religare Invesco Caterpillar Portfolio September 2015 1 Favorable Demographics Increase in India s working population 50% 48.25% Young working population compared to peers Median age of the population,

More information

General Insurance Industry in India

General Insurance Industry in India General Insurance Industry in India 2009 Casualty Loss Reserve Seminar September 14, 2009 Anita Sathe FCAS, FSA, MAAA ansathe@deloitte.com Contents History State of the market Removal of tariffs Key lines

More information

Investing in Healthcare in Vietnam. KPMG Vietnam Webinar 30 November 2017

Investing in Healthcare in Vietnam. KPMG Vietnam Webinar 30 November 2017 Investing in Healthcare in Vietnam KPMG Vietnam Webinar 30 November 2017 Investing in Healthcare in Vietnam Agenda 14:00-14:05 Introduction 14:05-14:15 Vietnam healthcare system at a glance 14:15-14:25

More information

Benefit proposal prepared for: Sample Proposal (3/17) PLANSTIN INC 5200 Meadows Rd Suite 150, Lake Oswego OR

Benefit proposal prepared for: Sample Proposal (3/17) PLANSTIN INC 5200 Meadows Rd Suite 150, Lake Oswego OR Benefit proposal prepared for: Sample Proposal (3/17) 2017 PLANSTIN INC 5200 Meadows Rd Suite 150, Lake Oswego OR 97035 888-920-7526 BENEFIT SOLUTIONS Thank you for your consideration in the Planstin Benefit

More information

THE FUTURE OF ROCKEFELLER INSIGHTS. David K. Song, M.D., Ph.D., CFA Senior Portfolio Manager and Managing Director

THE FUTURE OF ROCKEFELLER INSIGHTS. David K. Song, M.D., Ph.D., CFA Senior Portfolio Manager and Managing Director ROCKEFELLER INSIGHTS THE FUTURE OF H E A LT H C A R E David K. Song, M.D., Ph.D., CFA Senior Portfolio Manager and Managing Director Rolando Morillo Equity Analyst and Vice President R O C K C O.C O M

More information

Healthcare Sector The Stock Market SIM, Professor West. Yiping Yang, Lu Yu

Healthcare Sector The Stock Market SIM, Professor West. Yiping Yang, Lu Yu Healthcare Sector The Stock Market SIM, Professor West Yiping Yang, Lu Yu 1 Agenda Sector Overview Business and Economic Analysis Financial Analysis Valuation Analysis Recommendation 2 Sector Overview

More information